- Home
- PHAR vs AVBP Comparison
PHAR vs AVBP Comparison
Compare PHAR & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- AVBP
- Stock Information
- Founded
- PHAR 1988
- AVBP 2021
- Country
- PHAR Netherlands
- AVBP United States
- Employees
- PHAR N/A
- AVBP N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- AVBP
- Sector
- PHAR Health Care
- AVBP
- Exchange
- PHAR Nasdaq
- AVBP NYSE
- Market Cap
- PHAR 587.5M
- AVBP 617.4M
- IPO Year
- PHAR N/A
- AVBP 2024
- Fundamental
- Price
- PHAR $10.03
- AVBP $20.15
- Analyst Decision
- PHAR Strong Buy
- AVBP Strong Buy
- Analyst Count
- PHAR 3
- AVBP 6
- Target Price
- PHAR $30.00
- AVBP $39.00
- AVG Volume (30 Days)
- PHAR 3.0K
- AVBP 158.1K
- Earning Date
- PHAR 05-08-2025
- AVBP 05-20-2025
- Dividend Yield
- PHAR N/A
- AVBP N/A
- EPS Growth
- PHAR N/A
- AVBP N/A
- EPS
- PHAR N/A
- AVBP N/A
- Revenue
- PHAR $320,708,000.00
- AVBP N/A
- Revenue This Year
- PHAR $12.39
- AVBP $63.13
- Revenue Next Year
- PHAR $9.84
- AVBP N/A
- P/E Ratio
- PHAR N/A
- AVBP N/A
- Revenue Growth
- PHAR 24.13
- AVBP N/A
- 52 Week Low
- PHAR $6.65
- AVBP $15.47
- 52 Week High
- PHAR $11.07
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- PHAR 71.76
- AVBP 51.13
- Support Level
- PHAR $8.60
- AVBP $18.84
- Resistance Level
- PHAR $10.28
- AVBP $21.79
- Average True Range (ATR)
- PHAR 0.30
- AVBP 1.12
- MACD
- PHAR 0.17
- AVBP 0.00
- Stochastic Oscillator
- PHAR 88.79
- AVBP 44.50
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.